secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001558370-22-011475
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics appoints Douglas Manion as President and COO effective August 1, 2022
--------------------------------------------------------------------------------

- Douglas Manion appointed President and COO effective August 1, 2022; Neal Walker remains CEO.
- Receives annual base salary of $490,000, target annual bonus of 40% of salary.
- Granted stock options for 217,800 shares at $13.62 exercise price and RSU award for 62,300 shares.
- Equity awards vest over four years; severance includes 12 months base salary plus COBRA if terminated without cause.
- Previously EVP R&D at Arena Pharmaceuticals and held leadership roles at BMS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/0001558370-22-011475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/acrs-20220801x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-011475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer